Celgene: CA057-001 - A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480, BORTEZOMIB AND DEXAMETHASONE (480Vd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYE
Clinical Trial Grant
Awarded By
Celgene Corporation
Start Date
May 3, 2024
End Date
April 7, 2029
Awarded By
Celgene Corporation
Start Date
May 3, 2024
End Date
April 7, 2029